Ocrelizumab compared to rituximab for relapsing-remitting multiple sclerosis.

For relapsing-remitting multiple sclerosis, evidence shows that ocrelizumab and rituximab have comparable efficacy in preventing disease activity, although ocrelizumab may have a slightly better infection safety profile. Clinician choice may be influenced by treatment approval status, specific patient circumstances, and health economic considerations.